Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years
Latest Information Update: 14 Oct 2024
At a glance
- Drugs JNJ-78901563 (Primary)
- Indications Escherichia coli infections
- Focus Registrational; Therapeutic Use
- Acronyms E.mbrace
- Sponsors Janssen Research & Development; Janssen Vaccines and Prevention B.V
- 08 Oct 2024 Planned End Date changed from 29 Mar 2028 to 29 Jun 2029.
- 19 Sep 2024 Planned number of patients changed from 18556 to 19800.
- 19 Sep 2024 Planned End Date changed from 22 Nov 2027 to 29 Mar 2028.